Table 2.
Literature Review–Patient characteristics.
| LITERATURE REVIEW: PATIENT CHARACTERISTICS (N = 67) | |
|---|---|
| Gender | N = 67 |
| Male | 37 (55%) |
| Age | |
| Mean age at melanoma diagnosis (min–max) (years) | 58 (26–83) |
| Melanoma medical history | |
| Oncological approach | |
| Adjuvant | 25 (37%) |
| Metastatic | 42 (63%) |
| Type of immunotherapy | |
| Anti-CTLA-4 monotherapy | 19 (28%) |
| Anti-PD-1 monotherapy | 27 (40%) |
| Anti-CTLA-4 + Anti-PD-1 combined | 10 (15%) |
| Anti-PD-1 +/− Anti-CTLA-4 | 11 (16%) |
| Immune-induced granulomatosis | |
| Median time since initiation of ICI (min–max) (months) | 3 (1–43) |
| Thoracic involvement | 61 (91%) |
| Grade 1 impairment | 38 (63%) |
| Grade 2 impairment | 17 (28%) |
| Grade 3 or 4 impairment | 6 (10%) |
| Dermatological involvement | 32 (48%) |
| Lymph node invasion | 8 (12%) |
| Hepatic involvement | 2 (3%) |
| Bone involvement | 5 (7%) |
| Histological confirmation | 62 (93%) |
| Therapeutic management | |
| Systemic corticosteroids | 25 (37%) |
| Discontinuation of immunotherapy | 33 (49%) |
| Granulomatosis outcome | |
| Radiological outcome of granulomatosis | N = 62 |
| Stability | 8 (13%) |
| Partial or complete regression | 54 (87%) |
| Oncological outcome at the time of granulomatosis | |
| Patient in adjuvant condition | N = 25 |
| Relapse | 3 (12%) |
| Patients in metastatic stage | N = 42 |
| Objective response | 29 (69%) |
| Complete response | 16 (55%) |
| Partial response | 13 (45%) |
| Stability | 5 (12%) |
| Progression | 8 (19%) |
| Oncological outcome at last reported evaluation | |
| Mean follow-up time for melanoma (min–max) (months) | 8 (1–34) |
| Patient in adjuvant condition | N = 25 |
| Relapse | 3 (12%) |
| Patients in metastatic stage | N = 42 |
| Objective response | 24 (57%) |
| Complete response | 16 (67%) |
| Partial response | 8 (33%) |
| Stability | 4 (10%) |
| Progression | 14 (33%) |